Jornal Vascular Brasileiro
https://www.jvascbras.org/article/doi/10.1590/1677-5449.005518
Jornal Vascular Brasileiro
Review Article

Anticoagulantes orais diretos para o tratamento da trombose venosa profunda: revisão de revisões sistemáticas

Direct oral anticoagulants for treatment of deep vein thrombosis: overview of systematic reviews

Gustavo Muçouçah Sampaio Brandão, Raissa Carolina Fonseca Cândido, Hamilton de Almeida Rollo, Marcone Lima Sobreira, Daniela R. Junqueira

Downloads: 2
Views: 1500

Resumo

A number of limitations of standard therapy with warfarin for deep vein thrombosis (DVT) have been established. This overview of systematic reviews presents the baseline results for efficacy and safety of the new direct oral anticoagulants (DOACs) thrombin inhibitors, and activated factor X (Xa) inhibitors in patients with DVT. Searches were run on PubMed and the Cochrane Database of Systematic Reviews. Twenty-three studies were retrieved, and one systematic review was judged eligible. This review scored maximum according to AMSTAR criteria and included 7,596 patients for analysis of thrombin inhibitors and 16,356 patients for analysis of factor Xa inhibitors. The results of the meta-analysis indicate that DOACs are similar for DVT treatment when compared to standard treatment with warfarin. The incidence of major bleeding is somewhat lower in patients treated with factor Xa inhibitors and similar to standard therapy when treated with direct thrombin inhibitors.

Palavras-chave

direct oral anticoagulants; deep venous thrombosis; systematic review

Abstract

A terapia padrão com varfarina para a trombose venosa profunda (TVP) tem uma série de limitações já estabelecidas. Essa revisão de revisões sistemáticas elenca os principais resultados de eficácia e segurança dos anticoagulantes orais diretos (DOACs), inibidores da trombina e do fator X ativado (Xa), em pacientes com TVP. A pesquisa foi realizada nas bases PubMed e Cochrane Database of Systematic Reviews. Foram recuperados 23 estudos, e uma revisão sistemática foi considerada elegível. Essa revisão atingiu escore máximo no AMSTAR e incluiu 7.596 pacientes para análise dos inibidores da trombina e 16.356 pacientes para a análise dos inibidores do fator Xa. Os resultados da metanálise indicam que os DOACs apresentam eficácia similar à terapia padrão no tratamento da TVP. A incidência de sangramento maior é um pouco menor nos pacientes tratados com os inibidores do fator Xa e similar à terapia padrão no tratamento com inibidores diretos da trombina.

Keywords

anticoagulantes orais diretos; trombose venosa profunda; revisão sistemática.

References

1. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg. 2003;25(1):1-5. http://dx.doi.org/10.1053/ejvs.2002.1778. PMid:12525804.

2. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981;94(4 pt 1):439-44. http://dx.doi.org/10.7326/0003-4819-94-4-439. PMid:7212500.

3. Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis. 2006;21(1):41-8. http://dx.doi.org/10.1007/s11239-006-5574-9. PMid:16475040.

4. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. Chest. 2012;141(2, Suppl):e419S -94. http://dx.doi.org/10.1378/chest.11-2301. PMid:22315268.

5. Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2010;(9):CD001100. PMid:20824828.

6. Garcia D. Novel anticoagulants and the future of anticoagulation. Thromb Res. 2009;123(Suppl 4):S50-5. http://dx.doi.org/10.1016/S0049-3848(09)70144-6. PMid:19303505.

7. Marques MA. Os novos anticoagulantes orais no Brasil. J Vasc Bras. 2013;12(3):185-6. http://dx.doi.org/10.1590/jvb.2013.046.

8. Haas S. New anticoagulants - towards the development of an “ideal” anticoagulant. VASA Zeitschrift fur Gefasskrankheiten. 2009;38(1):13-29. http://dx.doi.org/10.1024/0301-1526.38.1.13. PMid:19229800.

9. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-52. http://dx.doi.org/10.1016/j.chest.2015.11.026. PMid:26867832.

10. Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia. 2005;60(6):565-74. http://dx.doi.org/10.1111/j.1365-2044.2005.04192.x. PMid:15918828.

11. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72(4):581-92. http://dx.doi.org/10.1111/j.1365-2125.2011.03916.x. PMid:21241354.

12. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1-22. http://dx.doi.org/10.2165/0003088-200948010-00001. PMid:19071881.

13. Shojania KG, Bero LA. Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. Eff Clin Pract. 2001;4(4):157-62. PMid:11525102.

14. Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One. 2007;2(12):e1350. http://dx.doi.org/10.1371/journal.pone.0001350. PMid:18159233.

15. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7(1):10. http://dx.doi.org/10.1186/1471-2288-7-10. PMid:17302989.

16. Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev. 2015;(6):CD010956. http://dx.doi.org/10.1002/14651858.CD010956.pub2. PMid:26123214.

17. AstraZeneca. AstraZeneca withdraws its application for Ximelagatran 36-mg film-coated tablets [Internet]. London: European Medicines Agency; 2006 [27 march 2016]. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/02/WC500074073. pdf

18. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-4. http://dx.doi.org/10.1111/j.1538-7836.2005.01204.x. PMid:15842354.

19. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490-4. http://dx.doi.org/10.1136/bmj.328.7454.1490. PMid:15205295.

20. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is ‘quality of evidence’ and why is it important to clinicians? BMJ. 2008;336(7651):995-8. http://dx.doi.org/10.1136/bmj.39490.551019.BE.

21. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6. http://dx.doi.org/10.1136/bmj.39489.470347. AD. PMid:18436948.

22. Brunton LL, Chabner BA, Knollmann BC. Coagulação sanguínea e fármacos anticoagulantes, fibrinolíticos e antiplaquetários. In: Weitz JI. As bases farmacológicas da terapêutica de Goodman & Gilman. 12. ed. Porto Alegre: Artmed; 2012. p. 849-76.

23. Food and Drug Administration. Approval letter – praxbind [Internet]. Silver Spring: FDA; 2018 [2018 jun 18]. https://www.accessdata. fda.gov/drugsatfda_docs/nda/2015/761025Orig1s000Approv.pdf

24. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446-51. http://dx.doi.org/10.1038/nm.3102. PMid:23455714.

25. Food and Drug Administration. Approval letter – andexxa [Internet]. Silver Spring: FDA; 2018 [2018 jun 18]. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM606693.pdf

26. Brasil. Agência Nacional de Vigilância Sanitária. Consulta a produtos registrados – consulta a medicamentos e hemoderivados - praxbind. Brasília: Anvisa; 2018 [2018 jun 18]. https://consultas.anvisa.gov. br/#/medicamentos/25351679654201513/?substancia=2599

27. Magalhães LP, Figueiredo MJO, Cintra FD, et al. II Diretrizes Brasileiras de Fibrilação Atrial. Arq Bras Cardiol. 2016;106(4, Supl.2):1-22. http://dx.doi.org/10.5935/abc.20160055. PMid:27487201.

28. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52. http://dx.doi.org/10.1056/NEJMoa0906598. PMid:19966341.

29. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. http://dx.doi.org/10.1056/NEJMoa1007903. PMid:21128814.

30. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. http://dx.doi.org/10.1056/NEJMoa1302507. PMid:23808982.

31. Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15. http://dx.doi.org/10.1056/NEJMoa1306638. PMid:23991658.

32. Brasil. Agência Nacional de Vigilância Sanitária. Consulta a produtos registrados – consulta a medicamentos e hemoderivados - lixiana [Internet]. Brasília: Anvisa; 2018 [2018 jun 18]. https://consultas.anvisa.gov.br/#/medicamentos/25351344356201415/?nomeProduto=Lixiana

33. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-24. http://dx.doi.org/10.1056/NEJMoa1711948. PMid:29231094.

34. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-23. http://dx.doi.org/10.1200/JCO.2018.78.8034. PMid:29746227.

35. ClinicalTrials. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO - ClinicalTrials.gov Identifier: NCT03045406). Italy: Fadoi Foundation; 2018. https://clinicaltrials.gov/ct2/show/NCT03045406

36. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
5cd18eb10e8825632e632f90 jvb Articles

J Vasc Bras

Share this page
Page Sections